Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — VialBase Research

Summary

Landmark Nature publication demonstrating that thymosin beta-4 (Tβ4, the full-length protein from which TB-500 is derived) promotes cardiac cell survival, migration, and repair after myocardial infarction in mice. This study identified the ILK pathway as a key mechanism and established Tβ4 as a potential cardiac repair agent.

Key Findings

• Tβ4 promotes survival of cardiomyocytes after ischemic injury via ILK/Akt pathway activation
• Stimulates migration of cardiac cells and endothelial cells
• Reduces scar size and improves cardiac function after MI in mouse models
• ILK (integrin-linked kinase) identified as the key downstream mediator
• Tβ4 is the most abundant actin-sequestering peptide in mammalian cells
• Treatment with exogenous Tβ4 after MI improved ejection fraction

Methodology

In-vitro studies using neonatal and adult cardiomyocytes to assess survival and migration with Tβ4 treatment. In-vivo mouse MI model with Tβ4 injection. Outcomes assessed via echocardiography, histology, and molecular pathway analysis (ILK, Akt phosphorylation).

Limitations

• Mouse model — cardiac repair differs significantly in humans
• Used full-length Tβ4 protein, not the TB-500 fragment (Ac-SDKP or amino acids 17-23)
• Acute treatment model — does not address chronic healing scenarios
• Translation to human cardiac repair has not been validated
• Dosing and route of administration not directly applicable to human use

Relevance to Content

Seminal paper establishing the scientific foundation for TB-500/Tβ4 healing properties. While the study uses full-length Tβ4 (not the TB-500 fragment specifically), it’s the most-cited reference for TB-500’s mechanism of action. Important caveat: TB-500 is a synthetic fragment, not identical to endogenous Tβ4.

See Also

• Parent compound: TB-500